Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib versus placebo for dermatomyositis
ChiCTR2000030591Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of baricitinib in dermatomyositis (DM) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: CDASI scoring. Started Dec 2019; status: recruiting.
02
Drugs
baricitinib
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on ChiCTR2000030591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030591.